Nutrineal Pd4 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend contains essential and non‑essential amino acids that are directly absorbed into the bloodstream after intraperitoneal administration. These amino acids serve as substrates for protein synthesis, support gluconeogenesis, and help maintain electrolyte and acid‑base balance, thereby addressing the nutritional needs of patients unable to ingest food.

The dose of Nutrineal Pd4 is determined by the prescribing clinician based on the patient’s weight, nutritional status, renal and hepatic function, and overall clinical condition. Healthcare professionals calculate the appropriate volume and rate of infusion to meet individual therapeutic goals.

Safety data for Nutrineal Pd4 in pregnancy and lactation are limited. It should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Nutrineal Pd4, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and the necessary import documentation.

Nutrineal Pd4 offers a comprehensive amino acid profile specifically formulated for intraperitoneal delivery, which can be advantageous in settings where intraperitoneal access is preferred. Compared with some standard parenteral nutrition solutions that may be administered intravenously, Nutrineal Pd4 provides targeted nutrient support with a formulation designed for peritoneal absorption.

Nutrineal Pd4 should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the container for any signs of damage or contamination, and allow the solution to reach room temperature if required by the administration protocol.

Nutrineal Pd4 is administered via intraperitoneal infusion using a sterile catheter or peritoneal dialysis set. The infusion rate and total volume are prescribed by the treating physician, and the procedure should be performed under aseptic conditions by trained healthcare personnel.

Serious risks include anaphylactic reactions, severe electrolyte disturbances, metabolic acidosis, hypernatremia, and renal dysfunction. Patients should be closely monitored for signs of allergic response, changes in renal function, and electrolyte imbalances throughout the infusion period.

Nutrineal Pd4 should be avoided in patients with known hypersensitivity to any of its amino acid components, uncontrolled severe electrolyte disorders, or those for whom intraperitoneal administration is contraindicated. Clinicians should also exercise caution in patients with severe renal or hepatic impairment.